Lilly

Fuji Film 手ぶら

Program

Educational Lecture

Clinical trial ABC(Designated Speaker)

How to write English manuscript(Designated Speaker)

Plenary Session

Commentary of the Japanese Classification of Gastric Carcinoma(Designated Speaker)

The Japanese Gastric Cancer Treatment Guidelines up-to-dateEnglish(Designated Speaker)

Symposium

EGJ tumor update: Topics from epidemiology and diagnosisEnglish(Public Subscription / Designated Speakers)

Detail

Recently, the incidence of esophagogastric junction carcinoma has been increasing. However, it is not clear how much it will increase in the future. In addition, there are many cases in which it is difficult to diagnose the precise location of the esophagogastric junction, especially in patients with esophageal hiatal hernia. In this session, the epidemiology and problems with diagnosing esophagogastric junctional carcinoma will be clarified.

EGJ tumor update: Topics from current treatmentEnglish(Public Subscription / Designated Speakers)

Detail

In the surgical treatment of cancer of the esophagogastric junction, the approach and extent of lymph node dissection remain controversial. In addition, recently ESD is often carried out for early cancer. In this session, the latest treatment for esophagogastric junction carcinoma, from early-stage cancer to advanced cancer, will be discussed.

New evidence for perioperative chemotherapyEnglish(Public Subscription / Designated Speakers)

Detail

In Japan, based on the results of ACTS-GC, administration of S-1 for one year has been considered the standard treatment after curative resection of Stage II / III gastric cancer. Thereafter, different approaches have been used in the development of treatment between Stage II and Stage III. Recently, the results of several clinical trials have been reported and new evidence has been established. In this session, the results of domestic and international clinical trials on perioperative chemotherapy will be presented and future standard therapy will be discussed.

The role of conversion surgeryEnglish(Public Subscription / Designated Speakers)

Detail

Conversion surgery aims at curative resection after responding to chemotherapy in patients with advanced gastric cancer for whom radical resection was judged to be impossible at the time of initial treatment. In the surgery, both the primary lesion and remaining metastatic lesions are excised. With the progress of chemotherapy, there are an increasing number of cases in which such strategy is performed, but there is no definitive evidence on its indication and efficacy. In this session, the significance of conversion surgery, especially based on results, will be demonstrated.

New insights in molecular profilingEnglish(Public Subscription / Designated Speakers)

Detail

Due to advances in molecular biological diagnostic methods, genetic analysis of gastric cancer has developed dramatically. Particularly in TCGA, gastric cancer is classified into four subtypes at the molecular level, and the classification method is being extensively studied all over the world as a breakthrough. Also, a new classification of gastric cancer based on molecular profiling has been proposed from various perspectives. In this session, current results of genetic profiling will be presented and the future prospects will be discussed.

Standard treatment for gastric cancer in the worldEnglish(Designated Speakers Only)

Detail

For locally advanced gastric cancer, gastrectomy with D2 dissection is regarded worldwide as the standard treatment, but the actual procedure varies from country to country. In addition, the positioning of laparoscopic and robotic surgery has not been determined. Similarly, in chemotherapy for advanced gastric cancer, treatments used in Western and Eastern countries differ partly due to differences in the availability of chemotherapeutic agents. In this session, current standard therapies will be presented by domestic and international experts and the possible development of future international treatments will be discussed.

Standard treatment for gastric cancer in the worldEnglish(Designated Speakers Only)

Joint symposium with the Japanese Society for Helicobacter Research(Designated Speakers Only)

Detail

As Helicobacter pylori and stomach cancer are closely associated, the Japan Gastric Cancer Association and the Japanese Association for Helicobacter Research will hold a joint symposium. The first round was held at the Japanese Association for Helicobacter Research in June 2018, and so this is the second round. The latest knowledge of H. pylori and gastric cancer around the world and the issues of gastric cancer screening in the era of H. Pylori eradication will be presented by experts from the Japanese Association for Helicobacter Research. Lectures will be given from the aspect of endoscopic and pathological diagnosis of stomach cancer after eradication, which clinicians are currently struggling with, by experts from the Japan Gastric Cancer Association. A deeper mutual understanding in both associations is expected.

Panel discussions

Pitfalls of stomach cancer diagnosisEnglish(Public Subscription / Designated Speakers)

Detail

Recently, endoscopic diagnosis for gastric cancer has made dramatic progress with the advent of image enhancement endoscopes, magnifying endoscopes and endocytoscopy. However, looking only at the trees without looking at the forest can cause important maters to be overlooked. The points to note in recent endoscopic diagnosis and pathological diagnosis which tend to be pitfalls will be discussed.

The role of splenic hilar lymph node dissection in proximal gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

Based on the results of JCOG 0110, splenectomy and splenic hilar lymph node dissection are not recommended for upper gastric cancer that does not infiltrate the greater curvature. On the other hand, gastrectomy with splenectomy is regarded as the standard treatment for upper gastric cancer infiltrating the greater curvature. However, it has been reported that postoperative complications such as pancreatic leakage occur at a high rate due to splenectomy. Several surgeons prefer splenic hilar lymph node dissection without splenectomy, but the significance of this procedure is not clear. In this session, the future standard treatment based on present evidence on the significance of splenectomy and splenic hilar lymph node dissection for upper gastric cancer will be discussed.

Treatment for gastric cancer in the elderlyEnglish(Public Subscription / Designated Speakers)

Detail

In recent years, with the aging of the population, the number of elder and super-elder patients with gastric cancer is increasing. Evidence in non-elderly patients can be applied to elderly patients who have a good general condition (fit), but how to treat patients who have slightly inferior general condition (vulnerable) or significantly inferior patients (frail) is still not established. In this session, optimal treatments for elderly patients with early gastric cancer to advanced gastric cancer will be discussed.

Virtual cancer board(Designated Speakers Only)

1) Early gastric cancer

2) Advanced gastric cancer

Detail

The contents of the latest version of the gastric cancer treatment guidelines have been revised to be more suitable for routine practice by a number of CQs. However, there are many cases in which the guidelines do not apply in actual practice. In this session, representative cases will be presented and the optimal treatment from the viewpoints of endoscopist, surgeon, medical oncologist and pathologist will be discussed.

Video workshops

Robotic surgery for gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

Robot gastrectomy is now covered by health insurance in Japan, but it is implemented at only a few facilities, and the procedures have not been standardized yet. In the future, it is necessary to standardize the procedures to some extent in order to safely promote robot gastrectomy. In this session, the procedure and results of robotic surgery will be demonstrated and the possibility of future standardization will be discussed.

Troubleshooting in laparoscopic gastrectomyEnglish(Public Subscription / Designated Speakers)

Detail

In the gastric cancer treatment guidelines laparoscopic surgery is recommended as an option for routine clinical practice for cStage I gastric cancer. However, laparoscopic surgery for excessive obesity and advanced cancer is still technically demanding and unexpected troubles are often encountered. In this session, how to avoid and how to deal with troubles will be demonstrated by an expert in laparoscopic surgery.

Current status and perspectives of para-aortic lymph node dissectionEnglish(Public Subscription / Designated Speakers)

Detail

Although the significance of prophylactic para-aortic lymph node dissection was disproved by the results of JCOG 9501, there are still many cases in which para-aortic lymph node dissection is performed after neo-adjuvant chemotherapy or conversion surgery. In these cases, a more sophisticated technique is required compared to prophylactic dissection, but it is extremely difficult to inherit the technology due to the small number of cases. In this session, the actual procedure of para-aortic lymph node dissection for such very difficult cases and the method to avoid trouble after surgery will be demonstrated. Also, the future prospects for para-aortic lymph node dissection will be discussed.

Workshops

Navigation surgery for gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

Navigation surgery has been clinically applied in various fields in recent years. In the field of gastric cancer, navigation using fluorescent dyes is used for sentinel lymph node biopsy and determination of the extent of lymph node dissection. In this session, a wide range of research on navigation surgery in gastric cancer will be demonstrated.

Establishment of QOL assessment after gastrectomyEnglish(Public Subscription / Designated Speakers)

Detail

There are various methods of assessing QOL after gastrectomy, but the evaluation sheet varies depending on the purpose of development of the sheet. The methods are roughly divided into two types: one is evaluating the general condition during the cancer treatment and the other is evaluating the post-gastrectomy syndrome. Also, the evaluation sheets differ in different regions. In this session, the current status and the problems of the QOL evaluation sheet will be discussed, and the possibility of developing evaluation sheets that can be used worldwide in the future will also be discussed.

Current status and outlook of palliative treatment (stent, chemotherapy, surgery, etc.)(Public Subscription / Designated Speakers)

Detail

Palliative treatment aimed at improving gastrointestinal obstruction is often required in cases of gastric outlet obstruction due to cancer progression and ileus due to peritoneal dissemination. However, it is not clear whether surgical methods are optimal or whether non-surgical methods such as stents are appropriate. In addition, radiation therapy is sometimes performed for hemostasis against bleeding from a tumor, but the efficacy of radiotherapy has not been clearly shown. In this session, the current situation and prospects for such palliative treatment will be demonstrated.

Evaluation of nutritional index and significance of interventionEnglish(Public Subscription / Designated Speakers)

Detail

In recent years, preoperative nutritional status has been reported to be associated with postoperative complications and survival outcomes. In addition, in the surgical treatment of gastric cancer, maintenance of postoperative nutritional status such as prevention of sarcopenia is considered important. However, there has been no definitive evaluation of the intervention effect of preoperative and postoperative nutritional treatment. In this session, the optimal nutritional indicators and effects of intervention in the treatment of gastric cancer will be discussed.

Chemotherapy with limited indicationEnglish(Public Subscription / Designated Speakers)

Detail

In clinical practice, there are many patients who can not adapt to standard treatment with guideline recommendation level 1 due to their general condition and background. To accommodate these patients, limited indications are recommended in the latest version of the guidelines. In addition, although it is included in the recommendation level 1, the evidence of FOLFOX therapy has not been demonstrated in Japan. In this session, the positioning of FOLFOX and S-1 monotherapy in the first-line treatment and indication of irinotecan and nab-paclitaxel in the second-line treatment will be discussed.

Treatment strategy for HER2-positive gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

In recent years, treatment with molecular targeting agents is positioned as the standard treatment for various carcinomas. In the first-line treatment of gastric cancer, trastuzumab for HER2 positive gastric cancer is used as the standard therapy. However, evidence has not yet been established for the second-line treatment and perioperative chemotherapy. Treatments using drugs other than trastuzumab for HER2 positive cancer are also being developed. In this session, new treatment strategies for HER2-positive gastric cancer will be discussed.

Treatment for peritoneal metastasisEnglish(Public Subscription / Designated Speakers)

Detail

Peritoneal dissemination is the most refractory metastasis pattern and various therapeutic strategies are under consideration. However, there is no clear evidence for the treatment of peritoneal metastasis from gastric cancer. In this session, the current treatments and the future treatment strategies including intraperitoneal chemotherapy will be discussed.

Treatment strategy for carcinoma of the gastric remnantEnglish(Public Subscription / Designated Speakers)

Detail

Surgery of remnant gastric cancer is technically demanding because the pattern of lymph node metastasis differs according to the previous disease and to the reconstructive methods used at initial surgery, and when there is infiltration into adjacent organs, combined resection is also required. Furthermore, it is reported that the prognosis of advanced remnant gastrointestinal cancer tends to be inferior to that of primary upper gastric cancer. Since most of the surgical procedures result in completion gastrectomy, compliance with postoperative adjuvant chemotherapy becomes poor, so the usefulness of preoperative treatment is drawing attention. In this session, the current treatment strategy for remnant gastric cancer and its results will be demonstrated and the future possibility of multimodality treatment will also be discussed.

The role of multidisciplinary team medical treatment for gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

Regarding the treatment of gastric cancer, in addition to doctors, nurses, and pharmacists, the involvement of dieticians also is extremely important. More recently, due to the increase in the number of elderly people, MSW intervention for patients who need social support has become an important issue. In this session, the efforts and effects of a multi-disciplinary team treatment approach for gastric cancer will be discussed.

Application of artificial intelligence in diagnosis of gastric cancerEnglish(Public Subscription / Designated Speakers)

Detail

In recent years, artificial intelligence has been applied to various fields in the medical world. Artificial intelligence is also used for endoscopic diagnosis and pathological diagnosis in gastric cancer. In this session, the application of artificial intelligence in a wide range of fields in the diagnosis and treatment of gastric cancer will be reported.

Clinicopathological findings and molecular profile of gastric cancer with a gastric mucin phenotypeEnglish(Public Subscription / Designated Speakers)

Detail

Gastric cancer is classified into gastric type, intestinal type, mixed type, and unclassifiable type in terms of mucous characteristics. Among them, it is reported that the gastric type shows unique characteristics in terms of clinicopathologic and molecular pathology, but a global consensus has not been reached. Gastric cancer is not a single tumor but can be considered as a generic term for a group of tumors consisting of several different types, and the pathology of gastric cancer is not simple. There are many unresolved problems regarding gastric type gastric cancer, including clinicopathological findings, endoscopic findings, prognosis (biological malignancy), and molecular abnormality. We believe that the clinicopathological and molecular pathological features of gastric cancer should be clarified at the meeting of the Japan Gastric Cancer Association. The clinical and pathological significance of gastric type gastric cancer is expected to be clarified.

Special Program

ASCO, ESMO, DDW update(Designated Speakers only)

Special Session

ASCO-GI reports, DDW reports(Designated Speakers only)

Patients advocacy session(Designated Speakers only)

Molecular biology for diagnosis and treatment of gastric cancerEnglish(Designated Speakers only)